Supply of specific batches of products by Alphapharm Pty Limited

Overview

The Therapeutic Goods Act 1989 (the Act) was enacted to ensure that therapeutic goods available in Australia are of acceptable quality and meet safety and efficacy standards. This legislation was introduced to address the problem of ensuring that therapeutic goods are appropriately regulated to protect public health and safety. The Act was enacted by the Parliament of Australia and aims to provide a comprehensive regulatory framework for the approval, supply, and monitoring of therapeutic goods in the country. This particular notice under sections 14 and 14A of the Act, issued by Mayada Kayali, a delegate of the Secretary to the Department of Health and Ageing, grants consent for Alphapharm Pty Limited to supply specific batches of nicotine patches that do not comply with certain labelling requirements, subject to specified conditions to ensure consumer safety and product integrity.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of entities, including individuals, companies, and other organisations involved in the importation, supply, and advertising of therapeutic goods in Australia. This includes the manufacturing, evaluation, and monitoring of therapeutic goods, as well as ensuring compliance with relevant standards and regulations. The Act applies nationally across the Commonwealth of Australia, and its provisions extend to all states and territories, providing a unified regulatory framework for therapeutic goods. Certain entities and therapeutic goods may be subject to exemptions or exclusions under the Act, such as those prescribed in Therapeutic Goods Orders, which can set specific criteria or thresholds for different types of therapeutic goods. Subordinate legislation and regulations can further extend or restrict the application of the Act by detailing specific requirements and procedures. This legislative framework ensures that therapeutic goods available in Australia meet safety, quality, and efficacy standards. In the specific case outlined, the Act’s application is demonstrated through a consent notice issued by a delegate of the Secretary to the Department of Health and Ageing. This consent allows Alphapharm Pty Limited to supply specific batches of nicotine patches that do not fully comply with certain labelling requirements, as outlined in Therapeutic Goods Order No. 69. The consent is conditional, requiring that the products meet all other aspects of the standard, that the affected sachets are appropriately marked, and that the consent applies only to the specified batches and quantities. This demonstrates the Act’s flexibility in allowing for specific exceptions under strict conditions, ensuring that public health is safeguarded while providing necessary allowances for operational realities.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 allow for the delegate of the Secretary to the Department of Health and Ageing to provide consent for specific batches of products that do not comply with the Therapeutic Goods Order No. 69 – General Requirements for Labelling for Medicines. In this particular notice, the delegate has granted consent to Alphapharm Pty Limited for supplying certain batches of nicotine patches. These batches, listed in Table 1, do not include the required prefixes for the batch number and expiry date on the sachets, which contravenes the labelling standards. The consent is specifically limited to the batches and quantities detailed in the table and is subject to three key conditions: the products must comply with all other aspects of the labelling standard, the affected sachets must be marked with the actual batch numbers and expiry dates, and the consent applies only to the batches and quantities listed. The obligations imposed by this consent are clear and specific. Alphapharm Pty Limited must ensure that all products supplied under this consent comply with the labelling requirements except for the specific issue noted with the batch number and expiry date prefixes. The company must also ensure that the affected sachets are properly marked with the actual batch numbers and expiry dates, thereby maintaining the integrity of the information provided to consumers. Additionally, the consent strictly applies only to the batches and quantities listed in Table 1, meaning that any deviation from these parameters would not be covered by this consent. Failure to comply with the conditions of this consent can result in significant legal consequences. While the Therapeutic Goods Act itself does not explicitly state penalties for breaches in this context, non-compliance with the conditions of consent could lead to regulatory action under the Act. This might include the suspension or revocation of the consent, fines, or other enforcement actions. Additionally, if the non-compliance results in harm to consumers or breaches public health safety standards, further civil or criminal penalties may be applicable under related legislation, such as the Crimes Act 1900 (Cth). The maximum penalties for such offences can vary, but they can include substantial fines and imprisonment, depending on the severity of the breach and the resulting harm.